ArticleInternational journal of urology : official journal of the Japanese Urological Association2026
Prediction of Postoperative Intravesical Recurrence Using Urine DNA Monitoring in Nonmuscular-Invasive Urothelial Bladder Cancer.
Article in International journal of urology : official journal of the Japanese Urological Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prediction of Postoperative Intravesical Recurrence Using Urine DNA Monitoring in Nonmuscular-Invasive Urothelial Bladder Cancer.International journal of urology : official journal of the Japanese Urological Association · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesConsidering the high frequency of intravesical recurrence in bladder urothelial carcinoma (UBC), accurate non-invasive biomarkers for recurrence prediction are needed for better management after transurethral surgery. This pilot study examined the usefulness of urine DNA for detecting and predicting intravesical recurrence in UBC.
methodsPatients with primary nonmuscle-invasive UBC were prospectively enrolled just after initial transurethral surgery. Genomic profiles were evaluated in resected specimens of the original tumor and in urine during follow-up. Urine DNA, urine cytology, and cystoscopy were all evaluated at 3-month intervals until 1 year postoperatively. Upon centrifuging urine samples into precipitation and supernatant fractions, we retrospectively evaluated urine DNA using a genomic panel established in our previous report.
resultsIn the 19 patients enrolled, intravesical recurrent tumors were detected in six patients by cystoscopy. Urine DNA was positive in all of the recurrence cases before or at the time of cystoscopic or cytological detection, whereas urine cytology did not test positive before cystoscopic recurrence. Both urine precipitation and supernatant samples tested positive in 5 of 6 recurrence cases, indicating no obvious differences in the fraction used. Urine DNA was positive in 4 of the 13 nonrecurrence cases, among which three tested negative following Bacille Calmette-Guerin therapy.
conclusionsUrine DNA as screened by our genomic panel may be useful for predicting and detecting intravesical recurrence in UBC. The simultaneous evaluation of urine precipitation and supernatant may enhance the clinical utility of urine DNA during surveillance for intravesical recurrence in UBC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.